Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий

1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort: The Framingham Heart Study. JAMA. 1994;271(11):840-4. 
DOI:10.1001/jama.1994.03510350050036
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 1998;82(7A):2N-9N. DOI:10.1016/s0002-9149(98)00583-9
3. Ezekowitz MD, Aikens TH, Nagarakanti R, Shapiro T. Atrial fibrillation: Outpatient presentation and management. Circulation. 2011;124(1):95-9. DOI:10.1161/CIRCULATIONAHA.110.967455
4. Shkolnikova MA, Jdanov DA, Ildarova RA, et al. Atrial fibrillation among Russian men and women aged 55 years and older: Prevalence, mortality, and associations with biomarkers in a population-based study. J Geriatr Cardiol. 2020;17(2):74-84. DOI:10.11909/j.issn.1671-5411.2020.02.002
5. Gerdts E, Wachtell K, Omvik P, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 2007;49(2):311-16. DOI:10.1161/01.HYP.0000254322.96189.85
6. Акрамова Э.Г. Спекл-трекинг эхокардиография при артериальной гипертензии. Практическая медицина. 2018;1(112):69-73 [Akramova EG. Spekl-treking ekhokardiografiia pri arterial'noi gipertenzii. Prakticheskaia meditsina. 2018;1(112):69-73 (in Russian)].
7. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation. Europace. 2008;10(6):668-73. DOI:10.1093/europace/eun124
8. Акрамова Э.Г. Проблемы диагностики коморбидных форм хронической обструктивной болезни легких. Научное обозрение. Медицинские науки. 2016;3:5-22 [Akramova EG. Problemy diagnostiki komorbidnykh form khronicheskoi obstruktivnoi bolezni legkikh. Nauchnoe obozrenie. Meditsinskie nauki. 2016;3:5-22 (in Russian)].
9. Акрамова Э.Г., Стручков П.В., Хамитов Р.Ф., Бакиров Р.С. Электро- и эхокардиографические признаки легочного сердца у больных хронической обструктивной болезнью легких с сопутствующей артериальной гипертензией. Пульмонология. 2013;4:46-51 [Akramova EG, ­Struchkov PV, Khamitov RF, Bakirov RS. Elektro- i ekhokardiograficheskie priznaki legochnogo serdtsa u bol'nykh khronicheskoi obstruktivnoi bolezn'iu legkikh s soputstvuiushchei arterial'noi gipertenziei. Pul'monologiia. 2013;4:46-51 (in Russian)]. DOI:10.18093/0869-0189-2013-0-4-46-51
10. Яровая Е.Б., Жарикова А.А., Бойцов С.А., и др. Современные вероятностно-статистические подходы к поиску вариантов нуклеотидной последовательности, ассоциированных с комплексными заболеваниями, «Генетика». Генетика. 2017;10:1153-69 [Iarovaia EB, Zharikova AA, Boitsov SA, et al. Sovremennye veroiatnostno-statisticheskie podkhody k poisku variantov nukleotidnoi posledovatel'nosti, assotsiirovannykh s kompleksnymi zabolevaniiami, “Genetika”. Genetika. 2017;10:1153-69 (in Russian)]. DOI:10.7868/s0016675817100083
11. Щербакова Н.В., Мешков А.Н., Бойцов С.А. Применение метода секвенирования экзомов для диагностики предрасположенности к комплексным заболеваниям в профилактической медицине. Кардиоваскулярная терапия и профилактика. 2013;12(6):24-8 [Shcherbakova NV, ­Meshkov AN, Boitsov SA. Primenenie metoda sekvenirovaniia ekzomov dlia diagnostiki predraspolozhennosti k kompleksnym zabolevaniiam v profilakticheskoi meditsine. Kardiovaskuliarnaia terapiia i ­profilaktika. 2013;12(6):24-8 (in Russian)]. DOI:10.15829/1728-8800-2013-6-24-28
12. Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(7):668-72. DOI:10.1111/j.1540-8167.2008.01118.x
13. Щербакова Н.В., Ершова А.И., Суворова А.А., и др. Возможности фармакогенетического тестирования в кардиологии на основе данных экзомного секвенирования. Рациональная фармакотерапия в кардиологии. 2014;10(6):646-50 [Shcherbakova NV, Ershova AI, Suvorova AA, et al. Vozmozhnosti farmakogeneticheskogo testirovaniia v kardiologii na osnove dannykh ekzomnogo sekvenirovaniia. Ratsional'naia farmakoterapiia v kardiologii. 2014;10(6):646-50 (in Russian)]. DOI:10.20996/1819-6446-2014-10-6-646-650
14. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. ­Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. DOI:10.26442/2075082X.2019.1.190179
15. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. DOI:10.1016/s0140-6736(05)17741-1
16. Муромцева Г.А., Концевая А.В., Константинов В.В., и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11 [Muromtseva GA, Kontsevaia AV, Konstantinov VV, et al. Rasprostranennost' faktorov riska neinfektsionnykh zabolevanii v rossiiskoi populiatsii v 2012–2013 gg. Rezul'taty issledovaniia ESSE-RF. Kardiovaskuliarnaia terapiia i profilaktika. 2014;13(6):4-11 (in Russian)]. DOI:10.15829/1728-8800-2014-6-4-11
17. Wong ND, Lopez VA, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med. 2007;167(22):2431-6. DOI:10.1001/archinte.167.22.2431
18. Dan GA, Badila E, Weiss E, et al. Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. Int J Cardiol. 2018;254:136-41. DOI:10.1016/j.ijcard.2017.10.092
19. Tanislav C, Milde S, Schwartzkopff S, et al. Baseline characteristics in stroke patients with atrial fibrillation: Clinical trials versus clinical practice. BMC Res Notes. 2015;8(1). DOI:10.1186/s13104-015-1237-2
20. Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: The BALKAN-AF survey. Sci Rep. 2016;6. DOI:10.1038/srep20432
21. Бойцов С.А., Лукьянов М.М., Якушин С.С., и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50 [Boitsov SA, Luk'ianov MM, Iakushin SS, et al. Registr kardiovaskuliarnykh zabolevanii (REKVAZA): diagnostika, sochetannaia serdechno-sosudistaia patologiia, soputstvuiushchie zabolevaniia i lechenie v usloviiakh real'noi ambulatorno-poliklinicheskoi praktiki. Kardiovaskuliarnaia terapiia i profilaktika. 2014;13(6):44-50 (in Russian)]. DOI:10.15829/1728-8800-2014-6-3-8
22. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. DOI:10.1016/S0140-6736(02)11911-8
23. Healey JS, Connolly SJ. Atrial fibrillation: Hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(10 Suppl. 1):9-14. DOI:10.1016/S0002-9149(03)00227-3
24. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: Diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52. DOI:10.1097/HJH.0b013e32834f03bf
25. Sciarretta S, Pontremoli R, Rosei EA, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: Data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2009;27(2):410-7. DOI:10.1097/HJH.0b013e32831bc764
26. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751-6. DOI:10.1016/S0140-6736(99)10327-1
27. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. DOI:10.1016/S0140-6736(98)05012-0
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. ­Lancet. 2002;359(9311):995-1003. DOI:10.1016/S0140-6736(02)08089-3
29. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-100. DOI:10.1378/chest.10-0134
30. Okin PM, Hille DA, Larstorp ACK, et al. Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension. 2015;66(2):368-73. DOI:10.1161/HYPERTENSIONAHA.115.05728
31. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152(2):217-22. DOI:10.1016/j.ahj.2006.01.007
32. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med. 2010;152(2):78-84. DOI:10.7326/0003-4819-152-2-201001190-00005
33. Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Hear Rhythm. 2010;7(9):1282-90. DOI:10.1016/j.hrthm.2010.05.010
34. Lau DH, Shipp NJ, Kelly DJ, et al. Atrial Arrhythmia in Ageing Spontaneously Hypertensive Rats: Unraveling the Substrate in Hypertension and Ageing. PLoS One. 2013;8(8). DOI:10.1371/journal.pone.0072416
35. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015
36. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011;91(1):265-325. DOI:10.1152/physrev.00031.2009
37. Choisy SCM, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension. 2007;49(3):498-505. DOI:10.1161/01.HYP.0000257123.95372.ab
38. Hohl M, Lau DH, Müller A, et al. Concomitant obesity and metabolic syndrome add to the atrial arrhythmogenic phenotype in male hypertensive rats. J Am Heart Assoc. 2017;6(9). DOI:10.1161/JAHA.117.006717
39. Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: Implications for development of atrial fibrillation. Eur Heart J. 2006;27(24):3045-56. DOI:10.1093/eurheartj/ehl360
40. Lau DH, Mackenzie L, Kelly DJ, et al. Short-term hypertension is associated with the development of atrial fibrillation substrate: A study in an ovine hypertensive model. Heart Rhythm. 2010;7(3):396-404. DOI:10.1016/j.hrthm.2009.11.031
41. Kim SJ, Choisy SCM, Barman P, et al. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol. 2011;4(5):761-9. DOI:10.1161/CIRCEP.111.964783
42. Pluteanu F, Heß J, Plackic J, et al. Early subcellular Ca2+ remodelling and increased propensity for Ca2+ alternans in left atrial myocytes from hypertensive rats. Cardiovasc Res. 2015;106(1):87-97. DOI:10.1093/cvr/cvv045
43. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: Signal transduction and basic electrophysiological mechanisms. Europace. 2008;10(2):238-41. DOI:10.1093/europace/eum283
44. Kistler PM, Davidson NC, Sanders P, et al. Absence of acute effects of angiotensin II on atrial electrophysiology in humans. J Am Coll Cardiol. 2005;45(1):154-6. DOI:10.1016/j.jacc.2004.10.002
45. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. ­Hypertension. 1998;32(6):976-82. DOI:10.1161/01.HYP.32.6.976
46. Wagner S, Dantz C, Flebbe H, et al. NADPH oxidase 2 mediates angiotensin II-dependent cellular arrhythmias via PKA and CaMKII. J Mol Cell Cardiol. 2014;75:206-15. DOI:10.1016/j.yjmcc.2014.07.011
47. Zankov DP, Omatsu-Kanbe M, Isono T, et al. Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation. 2006;113(10):1278‑86. DOI:10.1161/CIRCULATIONAHA.104.530592
48. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: The Framingham Heart Study. Circulation. 1994;89(2):724-30. DOI:10.1161/01.CIR.89.2.724
49. Verdecchia P, Reboldi GP, Gattobigio R, et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41(2):218-23. DOI:10.1161/01.HYP.0000052830.02773.E4
50. Toh N, Kanzaki H, Nakatani S, et al. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension. 2010;55(5):1150-6. DOI:10.1161/HYPERTENSIONAHA.109.137760
51. Tsang TSM, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636-44. DOI:10.1016/S0735-1097(02)02373-2
52. Medi C, Kalman JM, Spence SJ, et al. Atrial electrical and structural changes associated with longstanding hypertension in humans: Implications for the substrate for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(12):1317-24. DOI:10.1111/j.1540-8167.2011.02125.x
53. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/EURHEARTJ/EHY339
54. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013;310(9):959-68. DOI:10.1001/JAMA.2013.184182
55. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/EURHEARTJ/EHAA612
56. O’Brien E. Measurement of blood pressure. In: ABC of Hypertension. 5th ed. UK: BMJ/Blackwell Publishing, 2007.
57. Halfon M, Wuerzner G, Marques-Vidal P, et al. Use of oscillometric devices in atrial fibrillation: a comparison of three devices and invasive blood pressure measurement. Blood Press. 2018;27(1):48-55. DOI:10.1080/08037051.2017.1383852
58. Vertkin AL, Sycheva AS, Kebina AL, et al. Measurement of blood pressure using automatic monitors in patients with atrial fibrillation: a comparative analysis. Russ Med Inq. 2021;5(4):189-95. DOI:10.32364/2587-6821-2021-5-4-189-195
59. Clark CE, McDonagh STJ, McManus RJ. Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: systematic review and meta-analysis. J Hum Hypertens. 2019;33(5):352-64. DOI:10.1038/s41371-018-0153-z
60. Шубик Ю.В., Пивоваров В.В., Зайцев Г.К., и др. Измерение артериального давления на каждом ударе сердца при фибрилляции предсердий: новый шаг к персонализации лечения пациента. Вестник аритмологии. 2021;28(1):23-32 [Shubik IuV, Pivovarov VV, Zaitsev GK, et al. Izmerenie arterial'nogo davleniia na kazhdom udare serdtsa pri fibrilliatsii predserdii: novyi shag k personalizatsii lecheniia patsienta. Vestnik aritmologii. 2021;28(1):23-32 (in Russian)]. DOI:10.35336/VA-2021-1-23-32
61. Мареев В.Ю., Рогоза А.Н., Орлова Я.А. Возможности суточного мониторирования артериального давления у больных с хронической сердечной недостаточностью и постоянной формой мерцания предсердий. Кардиология. 2001;1:60-2 [Mareev VIu, Rogoza AN, Orlova IaA. Vozmozhnosti sutochnogo monitorirovaniia arterial'nogo davleniia u bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu i postoiannoi formoi mertsaniia predserdii. Kardiologiia. 2001;1:60-2 (in Russian)].
62. Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66. DOI:10.1097/HJH.0000000000000221
63. Kotecha D, Lip G. Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm. Hypertens Res. 2013;36(10):854-5. DOI:10.1038/HR.2013.59
64. Давыдкин И.Л., Золотовская И.А. Прогностическое значение суточного мониторирования артериального давления у пациентов с фибрилляцией предсердий, перенесших кардиоэмболический инсульт. Артериальная гипертензия. 2016;22(1):32-40 [Davydkin IL, Zolotovskaia IA. Prognosticheskoe znachenie sutochnogo monitorirovaniia arterial'nogo davleniia u patsientov s fibrilliatsiei predserdii, perenesshikh kardioembolicheskii insul't. Arterial'naia gipertenziia. 2016;22(1):32-40 (in Russian)]. DOI:10.18705/1607-419X-2016-22-1-32-40
65. Гориева Ш.Б., Рогоза А.Н. Точность измерения артериального давления при постоянной форме фибрилляции предсердий. РМЖ. 2013;12:629-33 [Gorieva ShB, Rogoza AN. Tochnost' izmereniia arterial'nogo davleniia pri postoiannoi forme fibrilliatsii predserdii. RMZh. 2013;12:629-33 (in Russian)].
66. Xiong Q, Proietti M, Senoo K, Lip GYH. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol. 2015;191:172-7. DOI:10.1016/j.ijcard.2015.05.011
67. Harris K, Edwards D, Mant J. How can we best detect atrial fibrillation? J R Coll Physicians Edinb. 2012;42(Suppl. 18):5-22. DOI:10.4997/jrcpe.2012.s02
68. Wiesel J, Wiesel D, Suri R, Messineo FC. The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. Pacing Clin Electrophysiol. 2004;27(5):639-43. DOI:10.1111/j.1540-8159.2004.00499.x
69. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens. 2009;22(8):848-52. DOI:10.1038/ajh.2009.98
70. Willits I, Keltie K, Craig J, Sims A. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: A NICE medical technology guidance. Appl Health Econ Health Policy. 2014;12(3):255-65. DOI:10.1007/s40258-014-0096-7
71. Stergiou GS, Karpettas N, Protogerou A, et al. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens. 2009;23(10):654-8. DOI:10.1038/jhh.2009.5
72. Bumgarner JM, Lambert CT, Hussein AA, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. J Am Coll Cardiol. 2018;71(21):2381-8. DOI:10.1016/j.jacc.2018.03.003
73. Tison GH, Sanchez JM, Ballinger B, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 2018;3(5):409-16. DOI:10.1001/jamacardio.2018.0136
74. Yan BP, Lai WHS, Chan CKY, et al. Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. J Am Heart Assoc. 2018;7(8). DOI:10.1161/JAHA.118.008585
75. Orchard J, Lowres N, Freedman SB, et al. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. Eur J Prev Cardiol. 2016;23(Suppl. 2):13-20. DOI:10.1177/2047487316670255
76. Brasier N, Raichle CJ, Dörr M, et al. Detection of atrial fibrillation with a smartphone camera: First prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019;21(1):41‑7. DOI:10.1093/europace/euy176
77. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167-76. DOI:10.1160/TH14-03-0231
78. William AD, Kanbour M, Callahan T, et al. Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: The iREAD Study. Hear Rhythm. 2018;15(10):1561-5. DOI:10.1016/j.hrthm.2018.06.037
79. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012;366(2):120-9. DOI:10.1056/nejmoa1105575
80. Gorenek B, Boriani G, Dan GA, et al. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace. 2018;20(6):895‑6. DOI:10.1093/europace/euy051
81. Pollak WM, Simmons JD, Interian A Jr, et al. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol. 2001;24(4):424-9. DOI:10.1046/j.1460-9592.2001.00424.x
82. Kaufman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. Hear Rhythm. 2012;9(8):1241-6. DOI:10.1016/j.hrthm.2012.03.017
83. Oakley C. Genesis of arrhythmias in the failing heart and therapeutic implications. Am J Cardiol. 1991;67(12):26-8. DOI:10.1016/0002-9149(91)90072-S
84. Панченко Е.П. Антитромботическая терапия в кардиологии. М.: ГРУППА РЕМЕДИУМ, 2019 [Panchenko EP. Antithrombotic therapy in cardiology. Moscow: GRUPPA REMEDIUM, 2019 (in Russian)].
85. Donal E, Lip GYH, Galderisi M, et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016;17(4):355-83. DOI:10.1093/ehjci/jev354
86. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-71. DOI:10.1093/ehjci/jev014
87. Bartel T, Erbel R. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J. 2001;22(22):2041-4. DOI:10.1053/euhj.2001.2943
88. Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest ­Endosc. 2009;69(2):271-7. DOI:10.1016/j.gie.2008.04.063
89. Rockey DC, Koch J, Cello JP, et al. Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. N Engl J Med. 1998;339(3):153-9. DOI:10.1056/nejm199807163390303
90. Choi JS, Choi JY, Cho HG, et al. Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy? Scand J Gastroenterol. 2013;48(6):657-62. DOI:10.3109/00365521.2013.792390
91. Dorian P, Singh BN. Upstream therapies to prevent atrial fibrillation. Eur Heart J. 2008;10(Suppl.):H11-31. DOI:10.1093/eurheartj/sun033
92. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-9. DOI:10.1016/j.jacc.2004.10.068
93. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens. 2008;26(3):403-11. DOI:10.1097/HJH.0b013e3282f35c67
94. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J. 2007;154(3):448-53. DOI:10.1016/j.ahj.2007.04.062
95. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/nejmoa0801317
96. Yuehui Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27(15):1841-6. DOI:10.1093/eurheartj/ehl135
97. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47(1):46-50. DOI:10.1097/01.fjc.0000193808.99773.28
98. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J ­Hypertens. 2008;21(9):1034-9. DOI:10.1038/ajh.2008.217
99. Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and ­atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2008;51(3):217-22. DOI:10.1097/FJC.0b013e318160b42a
100. Schneider MP, Hua TA, Böhm M, et al. Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. A Meta-Analysis. J Am Coll Cardiol. 2010;55(21):2299-307. DOI:10.1016/j.jacc.2010.01.043
101. Tveit A, Seljeflot I, Grundvold I, et al. Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation. Am J Cardiol. 2007;99(11):1544-8. DOI:10.1016/j.amjcard.2007.01.030
102. GISSI-AF Investigators; Disertori M, Latini R, Barlera S, et al. Valsartan for Prevention of Recurrent Atrial Fibrillation. N Engl J Med. 2009;360(16):1606-17. DOI:10.1056/nejmoa0805710
103. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46(1):21-8. DOI:10.1177/0091270005283284
104. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002;106(3):331-6. DOI:10.1161/01.CIR.0000022665.18619.83
105. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090-8. DOI:10.1016/j.ehj.2003.08.014
106. Haywood LJ, Ford CE, Crow RS, et al. Atrial Fibrillation at Baseline and During Follow-Up in ­ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54(22):2023-31. DOI:10.1016/j.jacc.2009.08.020
107. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol. 2005;45(11):1832‑9. DOI:10.1016/j.jacc.2004.11.070
108. Soeby-Land C, Dixen U, Therkelsen SK, Kjaer A. Increased plasma aldosterone during atrial fibrillation declines following cardioversion. Cardiology. 2011;118(4):239-44. DOI:10.1159/000328462
109. Vatutin NT, Shevelyok AN, Kravchenko IN. The role of hyperaldosteronemia in recurrent atrial fibrillation. Russ Heart J. 2016;15(3):161-5. DOI:10.18087/rhj.2016.3.2128
110. Sen Yang S, Han W, Zhou HY, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl). 2008;121(1):38-42. DOI:10.1097/00029330-200801010-00008
111. Yongjun Q, Huanzhang S, Wenxia Z, et al. From changes in local RAAS to structural remodeling of the left atrium: A beautiful cycle in atrial fibrillation. Herz. 2015;40(3):514-20. DOI:10.1007/s00059-013-4032-7
112. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med. 2003;348(14):1309-21. DOI:10.1056/nejmoa030207
113. Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603. DOI:10.1016/j.jacc.2011.11.063
114. Neefs J, van den Berg NWE, Limpens J, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. Int J Cardiol. 2017;231:155-61. DOI:10.1016/j.ijcard.2016.12.029
115. Shantsila E, Shahid F, Sun Y, et al. Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. J Am Heart Assoc. 2020;9(18):e016239. DOI:10.1161/JAHA.119.016239
116. Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol. 2000;36(1):139-46. DOI:10.1016/S0735-1097(00)00693-8
117. Nasr I, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J. 2007;28(4):457-62. DOI:10.1093/eurheartj/ehl484
118. Lertsburapa K, White CM, Kluger J, et al. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2008;135(2):405-11. DOI:10.1016/j.jtcvs.2007.08.049
119. Kourliouros A, Valencia O, Hosseini MT, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. J Thorac Cardiovasc Surg. 2011;141(1):244-8. DOI:10.1016/j.jtcvs.2010.06.006
120. Chen WT, Krishnan GM, Sood N, et al. Effect of statins on atrial fibrillation after cardiac surgery: A duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg. 2010;140(2):364-72. DOI:10.1016/j.jtcvs.2010.02.042
121. Kourliouros A, De Souza A, Roberts N, et al. Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery. Ann Thorac Surg. 2008;85(5):1515-20. DOI:10.1016/j.athoracsur.2008.01.040
122. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? Eur Heart J. 2012;33(4):436-43. DOI:10.1093/eurheartj/ehr362
123. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol. 2005;16(11):1189-94. DOI:10.1111/j.1540-8167.2005.50007.x
124. Антонченко И.В., Татарский Б.А., Родионов В.А., и др. Использование омега-3 полиненасыщенных жирных кислот при лечении пароксизмальных форм фибрилляции предсердий. Вестник аритмологии. 2008;53(53):5-11 [Antonchenko IV, Tatarskii BA, Rodionov VA, et al. Ispol'zovanie omega-3 polinenasyshchennykh zhirnykh kislot pri lechenii paroksizmal'nykh form fibrilliatsii predserdii. Vestnik aritmologii. 2008;53(53):5-11 (in Russian)].
125. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5(1):30-41. DOI:10.1038/ncpcardio1038
126. Bianconi L, Calò L, Mennuni M, et al. N-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: A randomized, double-blind, multicentre study. Europace. 2011;13(2):174-81. DOI:10.1093/europace/euq386
127. Mozaffarian D, Marchioli R, Macchia A, et al. Fish oil and postoperative atrial fibrillation: The omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012;308(19):2001-11. DOI:10.1001/jama.2012.28733
128. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace. 2011;13(4):473-9. DOI:10.1093/europace/euq439
129. Macchia A, Grancelli H, Varini S, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: Results of the forward (randomized trial to assess efficacy of pufa for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. J Am Coll Cardiol. 2013;61(4):463-8. DOI:10.1016/j.jacc.2012.11.021
130. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA. 2010;304(21):2363-72. DOI:10.1001/jama.2010.1735
131. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: Results of the RACE 3 trial. Eur Heart J. 2018;39(32):2987-96. DOI:10.1093/eurheartj/ehx739
132. Overvad TF, Rasmussen LH, Skjøth F, et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013;126(7). DOI:10.1016/j.amjmed.2012.11.024
133. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation the atherosclerosis risk in communities study. Circ Arrhythmia Electrophysiol. 2014;7(4):620‑5. DOI:10.1161/CIRCEP.113.001244
134. Murphy NF, MacIntyre K, Stewart S, et al. Long-term cardiovascular consequences of obesity: 20-Year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J. 2006;27(1):96-106. DOI:10.1093/eurheartj/ehi506
135. Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J. 2008;155(2):310-5. DOI:10.1016/j.ahj.2007.10.004
136. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. J Am Med Assoc. 2004;292(20):2471-7. DOI:10.1001/jama.292.20.2471
137. Baek YS, Yang PS, Kim TH, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2017;6(6). DOI:10.1161/JAHA.116.004705
138. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222-31. DOI:10.1016/j.jacc.2014.09.028
139. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA. 2013;310(19):2050-60. DOI:10.1001/jama.2013.280521
140. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159‑69. DOI:10.1016/j.jacc.2015.03.002
141. Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: A meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1(3):139-52. DOI:10.1016/j.jacep.2015.04.004
142. Winkle RA, Mead RH, Engel G, et al. Impact of obesity on atrial fibrillation ablation: Patient characteristics, long-term outcomes, and complications. Heart Rhythm. 2017;14(6):819-27. DOI:10.1016/j.hrthm.2017.02.023
143. Cha YM, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation. 2008;117(20):2583-90. DOI:10.1161/CIRCULATIONAHA.107.716712
144. Ettinger PO, Wu CF, La Cruz CD, et al. Arrhythmias and the ‘Holiday Heart’: Alcoholassociated cardiac rhythm disorders. Am Heart J. 1978;95(5):555-62. DOI:10.1016/0002-8703(78)90296-X
145. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: How much is too much? J Am Coll Cardiol. 2014;64(3):290-2. DOI:10.1016/j.jacc.2014.04.038
146. Liang Y, Mente A, Yusuf S, et al. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ. 2012;184(16). DOI:10.1503/cmaj.120412
147. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta-analysis. J Am Coll Cardiol. 2014;64(3):281-9. DOI:10.1016/j.jacc.2014.03.048
148. Overvad TF, Rasmussen LH, Skjøth F, et al. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013;99(15):1093-9. DOI:10.1136/heartjnl-2013-304036
149. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20-8. DOI:10.1056/nejmoa1817591
150. Cheng M, Hu Z, Lu X, et al. Caffeine Intake and Atrial Fibrillation Incidence: Dose Response Meta-analysis of Prospective Cohort Studies. Can J Cardiol. 2014;30(4):448-54. DOI:10.1016/j.cjca.2013.12.026
151. Lavie CJ, Thomas RJ, Squires RW, et al. Exercise Training and Cardiac Rehabilitation in Primary and Secondary Prevention of Coronary Heart Disease. Mayo Clin Proc. 2009;84(4):373-83. DOI:10.1016/s0025-6196(11)60548-x
152. Mont L. Arrhythmias and sport practice. Heart. 2010;96(5):398-405. DOI:10.1136/hrt.2008.160903
153. Menezes AR, Lavie CJ, De Schutter A, et al. Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. Prog Cardiovasc Dis. 2015;58(2):117-25. DOI:10.1016/j.pcad.2015.07.001
154. Karjalainen J, Kujala UM, Kaprio J, et al. Lone atrial fibrillation in vigorously exercising middle aged men: Case-control study. Br Med J. 1998;316(7147):1784-5. DOI:10.1136/bmj.316.7147.1784
155. Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J. 2008;29(1):71-8. DOI:10.1093/eurheartj/ehm555
156. Molina L, Mont L, Marrugat J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: A follow-up study. Europace. 2008;10(5):618-23. DOI:10.1093/europace/eun071
157. Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr Fibrillation. 2013;5(5):789. DOI:10.4022/jafib.789
158. Risom SS, Zwisler AD, Johansen PP, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database Syst Rev. 2017;2017(2). DOI:10.1002/14651858.CD011197.pub2
159. Youssef I, Kamran H, Yacoub M, et al. Obstructive Sleep Apnea as a Risk Factor for Atrial Fibrillation: A Meta-Analysis. J Sleep Disord Ther. 2018;7(1). DOI:10.4172/2167-0277.1000282
160. Linz D, McEvoy RD, Cowie MR, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment A Review. JAMA Cardiology. 2018;3(6):532-40. DOI:10.1001/jamacardio.2018.0095
161. Szymanski FM, Filipiak KJ, Platek AE, et al. Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations – a long-term prospective, cross-sectional cohort study. Sleep Breath. 2015;19(3):849-56. DOI:10.1007/s11325-014-1102-x
162. Abumuamar AM, Dorian P, Newman D, Shapiro CM. The prevalence of obstructive sleep apnea in patients with atrial fibrillation. Clin Cardiol. 2018;41(5):601-7. DOI:10.1002/clc.22933
163. Певзнер А.В., Байрамбеков Э.Ш., Литвин А.Ю., и др. Результаты применения терапии с созданием постоянного положительного давления воздуха в верхних дыхательных путях при лечении больных с фибрилляцией предсердий и синдромом обструктивного апноэ во время сна. Российский кардиологический журнал. 2017;7:111-6 [Pevzner AV, Bayrambekov ES, Litvin AYu, et al. Results of continuous positive upper airway pressure treatment in patients with atrial fibrillation and obstructive sleep apnea. Rossiiskii kardiologicheskii zhurnal. 2017;7:111-6 (in Russian)]. DOI:10.15829/1560-4071-2017-7-111-116
164. Kadhim K, Middeldorp ME, Elliott AD, et al. Self-Reported Daytime Sleepiness and Sleep-Disordered Breathing in Patients With Atrial Fibrillation: SNOozE-AF. Can J Cardiol. 2019;35(11):1457-64. DOI:10.1016/j.cjca.2019.07.627
165. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504. DOI:10.5664/jcsm.6506
166. Goudis CA, Ketikoglou DG. Obstructive sleep and atrial fibrillation: Pathophysiological mechanisms and therapeutic implications. Int J Cardiol. 2017;230:293-300. DOI:10.1016/j.ijcard.2016.12.120
167. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm. 2013;10(3):331-7. DOI:10.1016/j.hrthm.2012.11.015
168. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: A meta-analysis of observational studies. Europace. 2014;16(9):1309-14. DOI:10.1093/europace/euu066
169. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62(4):300-5. DOI:10.1016/j.jacc.2013.03.052
170. Qureshi WT, Nasir UB, Alqalyoobi S, et al. Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol. 2015;116(11):1767-73. DOI:10.1016/j.amjcard.2015.08.046
171. Shukla A, Aizer A, Holmes D, et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: A meta-analysis. JACC Clin Electrophysiol. 2015;1(1–2):41-51. DOI:10.1016/j.jacep.2015.02.014
172. Neilan TG, Farhad H, Dodson JA, et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2(6). DOI:10.1161/JAHA.113.000421
173. Хачатрян Н.Т., Елфимова Е.М., Михайлова О.О., и др. Длительная терапия положительным давлением в дыхательных путях у пациентов с различными формами фибрилляции предсердий и синдромом обструктивного апноэ сна. Кардиологический вестник. 2020;4:72-8 [Khachatrian NT, Elfimova EM, Mikhailova OO, et al. Dlitel'naia terapiia polozhitel'nym davleniem v dykhatel'nykh putiakh u patsientov s razlichnymi formami fibrilliatsii predserdii i sindromom obstruktivnogo apnoe sna. Kardiologicheskii vestnik. 2020;4:72-8 (in Russian)]. DOI:10.36396/ms.2020.15.4.010
174. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594 [Arakelian MG, Bokeriia LA, Vasil'eva EIu, et al. Fibrilliatsiia i trepetanie predserdii. Klinicheskie rekomendatsii 2020. Rossiiskii kardiologicheskii zhurnal. 2021;26(7):4594 (in Russian)]. DOI:10.15829/1560-4071-2021-4594
175. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anti-
coagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. ­Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0
176. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12). DOI:10.1093/eurheartj/ehr488
177. Al-Khatib SM, LaPointe NMA, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014;160(11):760-73. DOI:10.7326/M13-1467
178. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5.
179. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8. DOI:10.1016/j.jacc.2003.11.032
180. Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: A randomized double-blind placebo-controlled study. Eur Heart J. 2007;28(11):1351-7. DOI:10.1093/eurheartj/ehl544
181. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand. 1981;209(645S):23-8. DOI:10.1111/j.0954-6820.1981.tb02597.x
182. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38). DOI:10.1093/eurheartj/ehw210
183. Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC Heart Fail. 2013;1(1):21-8. DOI:10.1016/j.jchf.2012.09.002
184. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: Mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65(20):2239-51. DOI:10.1016/j.jacc.2015.03.557
185. Tribulova N, Okruhlicova L, Novakova S, et al. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. Exp Physiol. 2002;87(2):195-205. DOI:10.1113/eph8702336
186. Panikkath R, Reinier K, Uy-Evanado A, et al. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol. 2013;18(3):225-9. DOI:10.1111/anec.12003
187. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: Its arrhythmogenic potential. Heart. 2005;91(2):250-6. DOI:10.1136/hrt.2004.042473
188. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens. 1999;12(12 Suppl. 1):181S-8S. DOI:10.1016/s0895-7061(99)00106-5
189. Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: A review of the epidemiology, pathophysiology and clinical implications. J Hum Hypertens. 2008;22(6):380-8. DOI:10.1038/jhh.2008.10
190. Vaseghi M, Shivkumar K. The Role of the Autonomic Nervous System in Sudden Cardiac Death. Prog Cardiovasc Dis. 2008;50(6):404-19. DOI:10.1016/j.pcad.2008.01.003
191. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363-72. DOI:10.1136/heart.89.11.1363
192. Page RL. Newly Diagnosed Atrial Fibrillation. N Engl J Med. 2004;351(23):2408-16. DOI:10.1056/nejmcp041956
193. Bigger JT, Sahar DI. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol. 1987;59(11). DOI:10.1016/0002-9149(87)90195-0
194. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus Sotalol for Atrial Fibrillation. N Engl J Med. 2005;352(18):1861-72. DOI:10.1056/nejmoa041705
195. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-9. DOI:10.1161/CIRCULATIONAHA.111.019927
196. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction. N Engl J Med. 1989;321(6):406-12. DOI:10.1056/nejm198908103210629
197. Gao X, Guha A, Buck B, et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018;18(2):68-72. DOI:10.1016/j.ipej.2017.12.001
198. Миронова Е.С., Миронов Н.Ю., Миронова Н.А., и др. Электрофизиологические параметры сердца и результаты противоаритмического лечения у больных с пароксизмальной формой фибрилляции предсердий, идиопатической и в сочетании с гипертонической болезнью. Кардиология. 2019;59(8):39-46 [Mironova ES, Mironov NIu, Mironova NA, et al. Elektrofiziologicheskie parametry serdtsa i rezul'taty protivoaritmicheskogo lecheniia u bol'nykh s paroksizmal'noi formoi fibrilliatsii predserdii, idiopaticheskoi i v sochetanii s gipertonicheskoi bolezn'iu. Kardiologiia. 2019;59(8):39-46 (in ­Russian)]. DOI:10.18087/CARDIO.2019.8.N644
199. Alexopoulos A, Perpinia A, Michelakakis N, et al. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing. Ther Adv Cardiovasc Dis. 2010;4(5):295-9. DOI:10.1177/1753944710381603
200. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J. 1993;14(Suppl. H):88-92. DOI:10.1093/eurheartj/14.suppl_h.88
201. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest. N Engl J Med. 1994;330(26):1852-7. DOI:10.1056/nejm199406303302603
202. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. DOI:10.7326/0003-4819-150-9-200905050-00006
203. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766-72. DOI:10.1373/clinchem.2006.077180
204. Чазов Е.И. Заболевания сердечно-сосудистой системы (II). Под ред. акад. Е.И. Чазова. Руководство по кардиологии. В 4 т. Т. 4. М.: Практик, 2014 [Chazov EI. Diseases of the cardiovascular system (II). Ed. by academician EI Chazov. Manual of cardiology in four volumes. Vol. 4. Moscow: Praktik, 2014 (in Russian)].
205. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):S1-87. DOI:10.1016/j.kint.2020.11.003
206. Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J. 2007;28(7):836-41. DOI:10.1093/eurheartj/ehm027
207. Wokhlu A, Hodge DO, Monahan KH, et al. Long-term outcome of atrial fibrillation ablation: Impact and predictors of very late recurrence. J Cardiovasc Electrophysiol. 2010;21(10):1071-8. DOI:10.1111/j.1540-8167.2010.01786.x
208. Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence among Patients with Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323(3):248-55. DOI:10.1001/jama.2019.21187
209. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380(9838):238-46. DOI:10.1016/S0140-6736(12)60570-4
210. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47(2):219-33. DOI:10.1016/S0008-6363(00)00119-X
211. Olsson LG, Swedberg K, Ducharme A, et al. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol. 2006;47(10):1997-2004. DOI:10.1016/j.jacc.2006.01.060
212. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology. 1993;43(1):32-6. DOI:10.1212/wnl.43.1_part_1.32
213. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021:1-65. DOI:10.1093/europace/euab065
214. Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of cardiology working group on thrombosis. Eur Heart J. 2017;38(19):1455-62. DOI:10.1093/eurheartj/ehw454
215. Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding: A meta-analysis. Thromb Haemost. 2015;114(4):819-25. DOI:10.1160/TH15-01-0063
216. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(2):554-66. DOI:10.1007/s10620-020-06248-9
217. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. DOI:10.1093/eurheartj/ehy136

________________________________________________

1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort: The Framingham Heart Study. JAMA. 1994;271(11):840-4. 
DOI:10.1001/jama.1994.03510350050036
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 1998;82(7A):2N-9N. DOI:10.1016/s0002-9149(98)00583-9
3. Ezekowitz MD, Aikens TH, Nagarakanti R, Shapiro T. Atrial fibrillation: Outpatient presentation and management. Circulation. 2011;124(1):95-9. DOI:10.1161/CIRCULATIONAHA.110.967455
4. Shkolnikova MA, Jdanov DA, Ildarova RA, et al. Atrial fibrillation among Russian men and women aged 55 years and older: Prevalence, mortality, and associations with biomarkers in a population-based study. J Geriatr Cardiol. 2020;17(2):74-84. DOI:10.11909/j.issn.1671-5411.2020.02.002
5. Gerdts E, Wachtell K, Omvik P, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 2007;49(2):311-16. DOI:10.1161/01.HYP.0000254322.96189.85
6. Akramova EG. Spekl-treking ekhokardiografiia pri arterial'noi gipertenzii. Prakticheskaia meditsina. 2018;1(112):69-73 (in Russian).
7. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation. Europace. 2008;10(6):668-73. DOI:10.1093/europace/eun124
8. Akramova EG. Problemy diagnostiki komorbidnykh form khronicheskoi obstruktivnoi bolezni legkikh. Nauchnoe obozrenie. Meditsinskie nauki. 2016;3:5-22 (in Russian).
9. Akramova EG, ­Struchkov PV, Khamitov RF, Bakirov RS. Elektro- i ekhokardiograficheskie priznaki legochnogo serdtsa u bol'nykh khronicheskoi obstruktivnoi bolezn'iu legkikh s soputstvuiushchei arterial'noi gipertenziei. Pul'monologiia. 2013;4:46-51 (in Russian). DOI:10.18093/0869-0189-2013-0-4-46-51
10. Iarovaia EB, Zharikova AA, Boitsov SA, et al. Sovremennye veroiatnostno-statisticheskie podkhody k poisku variantov nukleotidnoi posledovatel'nosti, assotsiirovannykh s kompleksnymi zabolevaniiami, “Genetika”. Genetika. 2017;10:1153-69 (in Russian). DOI:10.7868/s0016675817100083
11. Shcherbakova NV, ­Meshkov AN, Boitsov SA. Primenenie metoda sekvenirovaniia ekzomov dlia diagnostiki predraspolozhennosti k kompleksnym zabolevaniiam v profilakticheskoi meditsine. Kardiovaskuliarnaia terapiia i ­profilaktika. 2013;12(6):24-8 (in Russian). DOI:10.15829/1728-8800-2013-6-24-28
12. Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(7):668-72. DOI:10.1111/j.1540-8167.2008.01118.x
13. Shcherbakova NV, Ershova AI, Suvorova AA, et al. Vozmozhnosti farmakogeneticheskogo testirovaniia v kardiologii na osnove dannykh ekzomnogo sekvenirovaniia. Ratsional'naia farmakoterapiia v kardiologii. 2014;10(6):646-50 (in Russian). DOI:10.20996/1819-6446-2014-10-6-646-650
14. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. ­Systemic Hypertension. 2019;16(1):6-31 (in Russian). DOI:10.26442/2075082X.2019.1.190179
15. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. DOI:10.1016/s0140-6736(05)17741-1
16. Muromtseva GA, Kontsevaia AV, Konstantinov VV, et al. Rasprostranennost' faktorov riska neinfektsionnykh zabolevanii v rossiiskoi populiatsii v 2012–2013 gg. Rezul'taty issledovaniia ESSE-RF. Kardiovaskuliarnaia terapiia i profilaktika. 2014;13(6):4-11 (in Russian). DOI:10.15829/1728-8800-2014-6-4-11
17. Wong ND, Lopez VA, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med. 2007;167(22):2431-6. DOI:10.1001/archinte.167.22.2431
18. Dan GA, Badila E, Weiss E, et al. Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. Int J Cardiol. 2018;254:136-41. DOI:10.1016/j.ijcard.2017.10.092
19. Tanislav C, Milde S, Schwartzkopff S, et al. Baseline characteristics in stroke patients with atrial fibrillation: Clinical trials versus clinical practice. BMC Res Notes. 2015;8(1). DOI:10.1186/s13104-015-1237-2
20. Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: The BALKAN-AF survey. Sci Rep. 2016;6. DOI:10.1038/srep20432
21. Boitsov SA, Luk'ianov MM, Iakushin SS, et al. Registr kardiovaskuliarnykh zabolevanii (REKVAZA): diagnostika, sochetannaia serdechno-sosudistaia patologiia, soputstvuiushchie zabolevaniia i lechenie v usloviiakh real'noi ambulatorno-poliklinicheskoi praktiki. Kardiovaskuliarnaia terapiia i profilaktika. 2014;13(6):44-50 (in Russian). DOI:10.15829/1728-8800-2014-6-3-8
22. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. DOI:10.1016/S0140-6736(02)11911-8
23. Healey JS, Connolly SJ. Atrial fibrillation: Hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(10 Suppl. 1):9-14. DOI:10.1016/S0002-9149(03)00227-3
24. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: Diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52. DOI:10.1097/HJH.0b013e32834f03bf
25. Sciarretta S, Pontremoli R, Rosei EA, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: Data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens. 2009;27(2):410-7. DOI:10.1097/HJH.0b013e32831bc764
26. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751-6. DOI:10.1016/S0140-6736(99)10327-1
27. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. DOI:10.1016/S0140-6736(98)05012-0
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. ­Lancet. 2002;359(9311):995-1003. DOI:10.1016/S0140-6736(02)08089-3
29. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-100. DOI:10.1378/chest.10-0134
30. Okin PM, Hille DA, Larstorp ACK, et al. Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension. 2015;66(2):368-73. DOI:10.1161/HYPERTENSIONAHA.115.05728
31. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152(2):217-22. DOI:10.1016/j.ahj.2006.01.007
32. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med. 2010;152(2):78-84. DOI:10.7326/0003-4819-152-2-201001190-00005
33. Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: Evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Hear Rhythm. 2010;7(9):1282-90. DOI:10.1016/j.hrthm.2010.05.010
34. Lau DH, Shipp NJ, Kelly DJ, et al. Atrial Arrhythmia in Ageing Spontaneously Hypertensive Rats: Unraveling the Substrate in Hypertension and Ageing. PLoS One. 2013;8(8). DOI:10.1371/journal.pone.0072416
35. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015
36. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011;91(1):265-325. DOI:10.1152/physrev.00031.2009
37. Choisy SCM, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension. 2007;49(3):498-505. DOI:10.1161/01.HYP.0000257123.95372.ab
38. Hohl M, Lau DH, Müller A, et al. Concomitant obesity and metabolic syndrome add to the atrial arrhythmogenic phenotype in male hypertensive rats. J Am Heart Assoc. 2017;6(9). DOI:10.1161/JAHA.117.006717
39. Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: Implications for development of atrial fibrillation. Eur Heart J. 2006;27(24):3045-56. DOI:10.1093/eurheartj/ehl360
40. Lau DH, Mackenzie L, Kelly DJ, et al. Short-term hypertension is associated with the development of atrial fibrillation substrate: A study in an ovine hypertensive model. Heart Rhythm. 2010;7(3):396-404. DOI:10.1016/j.hrthm.2009.11.031
41. Kim SJ, Choisy SCM, Barman P, et al. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol. 2011;4(5):761-9. DOI:10.1161/CIRCEP.111.964783
42. Pluteanu F, Heß J, Plackic J, et al. Early subcellular Ca2+ remodelling and increased propensity for Ca2+ alternans in left atrial myocytes from hypertensive rats. Cardiovasc Res. 2015;106(1):87-97. DOI:10.1093/cvr/cvv045
43. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: Signal transduction and basic electrophysiological mechanisms. Europace. 2008;10(2):238-41. DOI:10.1093/europace/eum283
44. Kistler PM, Davidson NC, Sanders P, et al. Absence of acute effects of angiotensin II on atrial electrophysiology in humans. J Am Coll Cardiol. 2005;45(1):154-6. DOI:10.1016/j.jacc.2004.10.002
45. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. ­Hypertension. 1998;32(6):976-82. DOI:10.1161/01.HYP.32.6.976
46. Wagner S, Dantz C, Flebbe H, et al. NADPH oxidase 2 mediates angiotensin II-dependent cellular arrhythmias via PKA and CaMKII. J Mol Cell Cardiol. 2014;75:206-15. DOI:10.1016/j.yjmcc.2014.07.011
47. Zankov DP, Omatsu-Kanbe M, Isono T, et al. Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation. 2006;113(10):1278‑86. DOI:10.1161/CIRCULATIONAHA.104.530592
48. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: The Framingham Heart Study. Circulation. 1994;89(2):724-30. DOI:10.1161/01.CIR.89.2.724
49. Verdecchia P, Reboldi GP, Gattobigio R, et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41(2):218-23. DOI:10.1161/01.HYP.0000052830.02773.E4
50. Toh N, Kanzaki H, Nakatani S, et al. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension. 2010;55(5):1150-6. DOI:10.1161/HYPERTENSIONAHA.109.137760
51. Tsang TSM, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636-44. DOI:10.1016/S0735-1097(02)02373-2
52. Medi C, Kalman JM, Spence SJ, et al. Atrial electrical and structural changes associated with longstanding hypertension in humans: Implications for the substrate for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(12):1317-24. DOI:10.1111/j.1540-8167.2011.02125.x
53. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/EURHEARTJ/EHY339
54. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA. 2013;310(9):959-68. DOI:10.1001/JAMA.2013.184182
55. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/EURHEARTJ/EHAA612
56. O’Brien E. Measurement of blood pressure. In: ABC of Hypertension. 5th ed. UK: BMJ/Blackwell Publishing, 2007.
57. Halfon M, Wuerzner G, Marques-Vidal P, et al. Use of oscillometric devices in atrial fibrillation: a comparison of three devices and invasive blood pressure measurement. Blood Press. 2018;27(1):48-55. DOI:10.1080/08037051.2017.1383852
58. Vertkin AL, Sycheva AS, Kebina AL, et al. Measurement of blood pressure using automatic monitors in patients with atrial fibrillation: a comparative analysis. Russ Med Inq. 2021;5(4):189-95. DOI:10.32364/2587-6821-2021-5-4-189-195
59. Clark CE, McDonagh STJ, McManus RJ. Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: systematic review and meta-analysis. J Hum Hypertens. 2019;33(5):352-64. DOI:10.1038/s41371-018-0153-z
60. Shubik IuV, Pivovarov VV, Zaitsev GK, et al. Izmerenie arterial'nogo davleniia na kazhdom udare serdtsa pri fibrilliatsii predserdii: novyi shag k personalizatsii lecheniia patsienta. Vestnik aritmologii. 2021;28(1):23-32 (in Russian). DOI:10.35336/VA-2021-1-23-32
61. Mareev VIu, Rogoza AN, Orlova IaA. Vozmozhnosti sutochnogo monitorirovaniia arterial'nogo davleniia u bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu i postoiannoi formoi mertsaniia predserdii. Kardiologiia. 2001;1:60-2 (in Russian).
62. Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66. DOI:10.1097/HJH.0000000000000221
63. Kotecha D, Lip G. Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm. Hypertens Res. 2013;36(10):854-5. DOI:10.1038/HR.2013.59
64. Davydkin IL, Zolotovskaia IA. Prognosticheskoe znachenie sutochnogo monitorirovaniia arterial'nogo davleniia u patsientov s fibrilliatsiei predserdii, perenesshikh kardioembolicheskii insul't. Arterial'naia gipertenziia. 2016;22(1):32-40 (in Russian). DOI:10.18705/1607-419X-2016-22-1-32-40
65. Gorieva ShB, Rogoza AN. Tochnost' izmereniia arterial'nogo davleniia pri postoiannoi forme fibrilliatsii predserdii. RMZh. 2013;12:629-33 (in Russian).
66. Xiong Q, Proietti M, Senoo K, Lip GYH. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol. 2015;191:172-7. DOI:10.1016/j.ijcard.2015.05.011
67. Harris K, Edwards D, Mant J. How can we best detect atrial fibrillation? J R Coll Physicians Edinb. 2012;42(Suppl. 18):5-22. DOI:10.4997/jrcpe.2012.s02
68. Wiesel J, Wiesel D, Suri R, Messineo FC. The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. Pacing Clin Electrophysiol. 2004;27(5):639-43. DOI:10.1111/j.1540-8159.2004.00499.x
69. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens. 2009;22(8):848-52. DOI:10.1038/ajh.2009.98
70. Willits I, Keltie K, Craig J, Sims A. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: A NICE medical technology guidance. Appl Health Econ Health Policy. 2014;12(3):255-65. DOI:10.1007/s40258-014-0096-7
71. Stergiou GS, Karpettas N, Protogerou A, et al. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens. 2009;23(10):654-8. DOI:10.1038/jhh.2009.5
72. Bumgarner JM, Lambert CT, Hussein AA, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. J Am Coll Cardiol. 2018;71(21):2381-8. DOI:10.1016/j.jacc.2018.03.003
73. Tison GH, Sanchez JM, Ballinger B, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 2018;3(5):409-16. DOI:10.1001/jamacardio.2018.0136
74. Yan BP, Lai WHS, Chan CKY, et al. Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. J Am Heart Assoc. 2018;7(8). DOI:10.1161/JAHA.118.008585
75. Orchard J, Lowres N, Freedman SB, et al. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. Eur J Prev Cardiol. 2016;23(Suppl. 2):13-20. DOI:10.1177/2047487316670255
76. Brasier N, Raichle CJ, Dörr M, et al. Detection of atrial fibrillation with a smartphone camera: First prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019;21(1):41‑7. DOI:10.1093/europace/euy176
77. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167-76. DOI:10.1160/TH14-03-0231
78. William AD, Kanbour M, Callahan T, et al. Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: The iREAD Study. Hear Rhythm. 2018;15(10):1561-5. DOI:10.1016/j.hrthm.2018.06.037
79. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012;366(2):120-9. DOI:10.1056/nejmoa1105575
80. Gorenek B, Boriani G, Dan GA, et al. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace. 2018;20(6):895‑6. DOI:10.1093/europace/euy051
81. Pollak WM, Simmons JD, Interian A Jr, et al. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol. 2001;24(4):424-9. DOI:10.1046/j.1460-9592.2001.00424.x
82. Kaufman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. Hear Rhythm. 2012;9(8):1241-6. DOI:10.1016/j.hrthm.2012.03.017
83. Oakley C. Genesis of arrhythmias in the failing heart and therapeutic implications. Am J Cardiol. 1991;67(12):26-8. DOI:10.1016/0002-9149(91)90072-S
84. Panchenko EP. Antithrombotic therapy in cardiology. Moscow: GRUPPA REMEDIUM, 2019 (in Russian).
85. Donal E, Lip GYH, Galderisi M, et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016;17(4):355-83. DOI:10.1093/ehjci/jev354
86. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-71. DOI:10.1093/ehjci/jev014
87. Bartel T, Erbel R. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J. 2001;22(22):2041-4. DOI:10.1053/euhj.2001.2943
88. Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest ­Endosc. 2009;69(2):271-7. DOI:10.1016/j.gie.2008.04.063
89. Rockey DC, Koch J, Cello JP, et al. Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. N Engl J Med. 1998;339(3):153-9. DOI:10.1056/nejm199807163390303
90. Choi JS, Choi JY, Cho HG, et al. Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy? Scand J Gastroenterol. 2013;48(6):657-62. DOI:10.3109/00365521.2013.792390
91. Dorian P, Singh BN. Upstream therapies to prevent atrial fibrillation. Eur Heart J. 2008;10(Suppl.):H11-31. DOI:10.1093/eurheartj/sun033
92. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-9. DOI:10.1016/j.jacc.2004.10.068
93. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens. 2008;26(3):403-11. DOI:10.1097/HJH.0b013e3282f35c67
94. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J. 2007;154(3):448-53. DOI:10.1016/j.ahj.2007.04.062
95. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/nejmoa0801317
96. Yuehui Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27(15):1841-6. DOI:10.1093/eurheartj/ehl135
97. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47(1):46-50. DOI:10.1097/01.fjc.0000193808.99773.28
98. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J ­Hypertens. 2008;21(9):1034-9. DOI:10.1038/ajh.2008.217
99. Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and ­atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2008;51(3):217-22. DOI:10.1097/FJC.0b013e318160b42a
100. Schneider MP, Hua TA, Böhm M, et al. Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. A Meta-Analysis. J Am Coll Cardiol. 2010;55(21):2299-307. DOI:10.1016/j.jacc.2010.01.043
101. Tveit A, Seljeflot I, Grundvold I, et al. Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation. Am J Cardiol. 2007;99(11):1544-8. DOI:10.1016/j.amjcard.2007.01.030
102. GISSI-AF Investigators; Disertori M, Latini R, Barlera S, et al. Valsartan for Prevention of Recurrent Atrial Fibrillation. N Engl J Med. 2009;360(16):1606-17. DOI:10.1056/nejmoa0805710
103. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46(1):21-8. DOI:10.1177/0091270005283284
104. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002;106(3):331-6. DOI:10.1161/01.CIR.0000022665.18619.83
105. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090-8. DOI:10.1016/j.ehj.2003.08.014
106. Haywood LJ, Ford CE, Crow RS, et al. Atrial Fibrillation at Baseline and During Follow-Up in ­ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54(22):2023-31. DOI:10.1016/j.jacc.2009.08.020
107. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol. 2005;45(11):1832‑9. DOI:10.1016/j.jacc.2004.11.070
108. Soeby-Land C, Dixen U, Therkelsen SK, Kjaer A. Increased plasma aldosterone during atrial fibrillation declines following cardioversion. Cardiology. 2011;118(4):239-44. DOI:10.1159/000328462
109. Vatutin NT, Shevelyok AN, Kravchenko IN. The role of hyperaldosteronemia in recurrent atrial fibrillation. Russ Heart J. 2016;15(3):161-5. DOI:10.18087/rhj.2016.3.2128
110. Sen Yang S, Han W, Zhou HY, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl). 2008;121(1):38-42. DOI:10.1097/00029330-200801010-00008
111. Yongjun Q, Huanzhang S, Wenxia Z, et al. From changes in local RAAS to structural remodeling of the left atrium: A beautiful cycle in atrial fibrillation. Herz. 2015;40(3):514-20. DOI:10.1007/s00059-013-4032-7
112. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med. 2003;348(14):1309-21. DOI:10.1056/nejmoa030207
113. Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603. DOI:10.1016/j.jacc.2011.11.063
114. Neefs J, van den Berg NWE, Limpens J, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. Int J Cardiol. 2017;231:155-61. DOI:10.1016/j.ijcard.2016.12.029
115. Shantsila E, Shahid F, Sun Y, et al. Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. J Am Heart Assoc. 2020;9(18):e016239. DOI:10.1161/JAHA.119.016239
116. Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol. 2000;36(1):139-46. DOI:10.1016/S0735-1097(00)00693-8
117. Nasr I, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis. Eur Heart J. 2007;28(4):457-62. DOI:10.1093/eurheartj/ehl484
118. Lertsburapa K, White CM, Kluger J, et al. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2008;135(2):405-11. DOI:10.1016/j.jtcvs.2007.08.049
119. Kourliouros A, Valencia O, Hosseini MT, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. J Thorac Cardiovasc Surg. 2011;141(1):244-8. DOI:10.1016/j.jtcvs.2010.06.006
120. Chen WT, Krishnan GM, Sood N, et al. Effect of statins on atrial fibrillation after cardiac surgery: A duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg. 2010;140(2):364-72. DOI:10.1016/j.jtcvs.2010.02.042
121. Kourliouros A, De Souza A, Roberts N, et al. Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery. Ann Thorac Surg. 2008;85(5):1515-20. DOI:10.1016/j.athoracsur.2008.01.040
122. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? Eur Heart J. 2012;33(4):436-43. DOI:10.1093/eurheartj/ehr362
123. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol. 2005;16(11):1189-94. DOI:10.1111/j.1540-8167.2005.50007.x
124. Antonchenko IV, Tatarskii BA, Rodionov VA, et al. Ispol'zovanie omega-3 polinenasyshchennykh zhirnykh kislot pri lechenii paroksizmal'nykh form fibrilliatsii predserdii. Vestnik aritmologii. 2008;53(53):5-11 (in Russian).
125. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5(1):30-41. DOI:10.1038/ncpcardio1038
126. Bianconi L, Calò L, Mennuni M, et al. N-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: A randomized, double-blind, multicentre study. Europace. 2011;13(2):174-81. DOI:10.1093/europace/euq386
127. Mozaffarian D, Marchioli R, Macchia A, et al. Fish oil and postoperative atrial fibrillation: The omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012;308(19):2001-11. DOI:10.1001/jama.2012.28733
128. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace. 2011;13(4):473-9. DOI:10.1093/europace/euq439
129. Macchia A, Grancelli H, Varini S, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: Results of the forward (randomized trial to assess efficacy of pufa for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. J Am Coll Cardiol. 2013;61(4):463-8. DOI:10.1016/j.jacc.2012.11.021
130. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA. 2010;304(21):2363-72. DOI:10.1001/jama.2010.1735
131. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: Results of the RACE 3 trial. Eur Heart J. 2018;39(32):2987-96. DOI:10.1093/eurheartj/ehx739
132. Overvad TF, Rasmussen LH, Skjøth F, et al. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med. 2013;126(7). DOI:10.1016/j.amjmed.2012.11.024
133. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation the atherosclerosis risk in communities study. Circ Arrhythmia Electrophysiol. 2014;7(4):620‑5. DOI:10.1161/CIRCEP.113.001244
134. Murphy NF, MacIntyre K, Stewart S, et al. Long-term cardiovascular consequences of obesity: 20-Year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J. 2006;27(1):96-106. DOI:10.1093/eurheartj/ehi506
135. Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J. 2008;155(2):310-5. DOI:10.1016/j.ahj.2007.10.004
136. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. J Am Med Assoc. 2004;292(20):2471-7. DOI:10.1001/jama.292.20.2471
137. Baek YS, Yang PS, Kim TH, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2017;6(6). DOI:10.1161/JAHA.116.004705
138. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222-31. DOI:10.1016/j.jacc.2014.09.028
139. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA. 2013;310(19):2050-60. DOI:10.1001/jama.2013.280521
140. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159‑69. DOI:10.1016/j.jacc.2015.03.002
141. Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: A meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1(3):139-52. DOI:10.1016/j.jacep.2015.04.004
142. Winkle RA, Mead RH, Engel G, et al. Impact of obesity on atrial fibrillation ablation: Patient characteristics, long-term outcomes, and complications. Heart Rhythm. 2017;14(6):819-27. DOI:10.1016/j.hrthm.2017.02.023
143. Cha YM, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation. 2008;117(20):2583-90. DOI:10.1161/CIRCULATIONAHA.107.716712
144. Ettinger PO, Wu CF, La Cruz CD, et al. Arrhythmias and the ‘Holiday Heart’: Alcoholassociated cardiac rhythm disorders. Am Heart J. 1978;95(5):555-62. DOI:10.1016/0002-8703(78)90296-X
145. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: How much is too much? J Am Coll Cardiol. 2014;64(3):290-2. DOI:10.1016/j.jacc.2014.04.038
146. Liang Y, Mente A, Yusuf S, et al. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ. 2012;184(16). DOI:10.1503/cmaj.120412
147. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta-analysis. J Am Coll Cardiol. 2014;64(3):281-9. DOI:10.1016/j.jacc.2014.03.048
148. Overvad TF, Rasmussen LH, Skjøth F, et al. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013;99(15):1093-9. DOI:10.1136/heartjnl-2013-304036
149. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20-8. DOI:10.1056/nejmoa1817591
150. Cheng M, Hu Z, Lu X, et al. Caffeine Intake and Atrial Fibrillation Incidence: Dose Response Meta-analysis of Prospective Cohort Studies. Can J Cardiol. 2014;30(4):448-54. DOI:10.1016/j.cjca.2013.12.026
151. Lavie CJ, Thomas RJ, Squires RW, et al. Exercise Training and Cardiac Rehabilitation in Primary and Secondary Prevention of Coronary Heart Disease. Mayo Clin Proc. 2009;84(4):373-83. DOI:10.1016/s0025-6196(11)60548-x
152. Mont L. Arrhythmias and sport practice. Heart. 2010;96(5):398-405. DOI:10.1136/hrt.2008.160903
153. Menezes AR, Lavie CJ, De Schutter A, et al. Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. Prog Cardiovasc Dis. 2015;58(2):117-25. DOI:10.1016/j.pcad.2015.07.001
154. Karjalainen J, Kujala UM, Kaprio J, et al. Lone atrial fibrillation in vigorously exercising middle aged men: Case-control study. Br Med J. 1998;316(7147):1784-5. DOI:10.1136/bmj.316.7147.1784
155. Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J. 2008;29(1):71-8. DOI:10.1093/eurheartj/ehm555
156. Molina L, Mont L, Marrugat J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: A follow-up study. Europace. 2008;10(5):618-23. DOI:10.1093/europace/eun071
157. Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr Fibrillation. 2013;5(5):789. DOI:10.4022/jafib.789
158. Risom SS, Zwisler AD, Johansen PP, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database Syst Rev. 2017;2017(2). DOI:10.1002/14651858.CD011197.pub2
159. Youssef I, Kamran H, Yacoub M, et al. Obstructive Sleep Apnea as a Risk Factor for Atrial Fibrillation: A Meta-Analysis. J Sleep Disord Ther. 2018;7(1). DOI:10.4172/2167-0277.1000282
160. Linz D, McEvoy RD, Cowie MR, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment A Review. JAMA Cardiology. 2018;3(6):532-40. DOI:10.1001/jamacardio.2018.0095
161. Szymanski FM, Filipiak KJ, Platek AE, et al. Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations – a long-term prospective, cross-sectional cohort study. Sleep Breath. 2015;19(3):849-56. DOI:10.1007/s11325-014-1102-x
162. Abumuamar AM, Dorian P, Newman D, Shapiro CM. The prevalence of obstructive sleep apnea in patients with atrial fibrillation. Clin Cardiol. 2018;41(5):601-7. DOI:10.1002/clc.22933
163. Pevzner AV, Bayrambekov ES, Litvin AYu, et al. Results of continuous positive upper airway pressure treatment in patients with atrial fibrillation and obstructive sleep apnea. Rossiiskii kardiologicheskii zhurnal. 2017;7:111-6 (in Russian). DOI:10.15829/1560-4071-2017-7-111-116
164. Kadhim K, Middeldorp ME, Elliott AD, et al. Self-Reported Daytime Sleepiness and Sleep-Disordered Breathing in Patients With Atrial Fibrillation: SNOozE-AF. Can J Cardiol. 2019;35(11):1457-64. DOI:10.1016/j.cjca.2019.07.627
165. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504. DOI:10.5664/jcsm.6506
166. Goudis CA, Ketikoglou DG. Obstructive sleep and atrial fibrillation: Pathophysiological mechanisms and therapeutic implications. Int J Cardiol. 2017;230:293-300. DOI:10.1016/j.ijcard.2016.12.120
167. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm. 2013;10(3):331-7. DOI:10.1016/j.hrthm.2012.11.015
168. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: A meta-analysis of observational studies. Europace. 2014;16(9):1309-14. DOI:10.1093/europace/euu066
169. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62(4):300-5. DOI:10.1016/j.jacc.2013.03.052
170. Qureshi WT, Nasir UB, Alqalyoobi S, et al. Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol. 2015;116(11):1767-73. DOI:10.1016/j.amjcard.2015.08.046
171. Shukla A, Aizer A, Holmes D, et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: A meta-analysis. JACC Clin Electrophysiol. 2015;1(1–2):41-51. DOI:10.1016/j.jacep.2015.02.014
172. Neilan TG, Farhad H, Dodson JA, et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2(6). DOI:10.1161/JAHA.113.000421
173. Khachatrian NT, Elfimova EM, Mikhailova OO, et al. Dlitel'naia terapiia polozhitel'nym davleniem v dykhatel'nykh putiakh u patsientov s razlichnymi formami fibrilliatsii predserdii i sindromom obstruktivnogo apnoe sna. Kardiologicheskii vestnik. 2020;4:72-8 (in Russian). DOI:10.36396/ms.2020.15.4.010
174. Arakelian MG, Bokeriia LA, Vasil'eva EIu, et al. Fibrilliatsiia i trepetanie predserdii. Klinicheskie rekomendatsii 2020. Rossiiskii kardiologicheskii zhurnal. 2021;26(7):4594 (in Russian). DOI:10.15829/1560-4071-2021-4594
175. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. ­Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0
176. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12). DOI:10.1093/eurheartj/ehr488
177. Al-Khatib SM, LaPointe NMA, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014;160(11):760-73. DOI:10.7326/M13-1467
178. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5.
179. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8. DOI:10.1016/j.jacc.2003.11.032
180. Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: A randomized double-blind placebo-controlled study. Eur Heart J. 2007;28(11):1351-7. DOI:10.1093/eurheartj/ehl544
181. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand. 1981;209(645S):23-8. DOI:10.1111/j.0954-6820.1981.tb02597.x
182. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38). DOI:10.1093/eurheartj/ehw210
183. Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC Heart Fail. 2013;1(1):21-8. DOI:10.1016/j.jchf.2012.09.002
184. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: Mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65(20):2239-51. DOI:10.1016/j.jacc.2015.03.557
185. Tribulova N, Okruhlicova L, Novakova S, et al. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. Exp Physiol. 2002;87(2):195-205. DOI:10.1113/eph8702336
186. Panikkath R, Reinier K, Uy-Evanado A, et al. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol. 2013;18(3):225-9. DOI:10.1111/anec.12003
187. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: Its arrhythmogenic potential. Heart. 2005;91(2):250-6. DOI:10.1136/hrt.2004.042473
188. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens. 1999;12(12 Suppl. 1):181S-8S. DOI:10.1016/s0895-7061(99)00106-5
189. Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: A review of the epidemiology, pathophysiology and clinical implications. J Hum Hypertens. 2008;22(6):380-8. DOI:10.1038/jhh.2008.10
190. Vaseghi M, Shivkumar K. The Role of the Autonomic Nervous System in Sudden Cardiac Death. Prog Cardiovasc Dis. 2008;50(6):404-19. DOI:10.1016/j.pcad.2008.01.003
191. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363-72. DOI:10.1136/heart.89.11.1363
192. Page RL. Newly Diagnosed Atrial Fibrillation. N Engl J Med. 2004;351(23):2408-16. DOI:10.1056/nejmcp041956
193. Bigger JT, Sahar DI. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol. 1987;59(11). DOI:10.1016/0002-9149(87)90195-0
194. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus Sotalol for Atrial Fibrillation. N Engl J Med. 2005;352(18):1861-72. DOI:10.1056/nejmoa041705
195. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-9. DOI:10.1161/CIRCULATIONAHA.111.019927
196. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction. N Engl J Med. 1989;321(6):406-12. DOI:10.1056/nejm198908103210629
197. Gao X, Guha A, Buck B, et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018;18(2):68-72. DOI:10.1016/j.ipej.2017.12.001
198. Mironova ES, Mironov NIu, Mironova NA, et al. Elektrofiziologicheskie parametry serdtsa i rezul'taty protivoaritmicheskogo lecheniia u bol'nykh s paroksizmal'noi formoi fibrilliatsii predserdii, idiopaticheskoi i v sochetanii s gipertonicheskoi bolezn'iu. Kardiologiia. 2019;59(8):39-46 (in ­Russian). DOI:10.18087/CARDIO.2019.8.N644
199. Alexopoulos A, Perpinia A, Michelakakis N, et al. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing. Ther Adv Cardiovasc Dis. 2010;4(5):295-9. DOI:10.1177/1753944710381603
200. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J. 1993;14(Suppl. H):88-92. DOI:10.1093/eurheartj/14.suppl_h.88
201. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest. N Engl J Med. 1994;330(26):1852-7. DOI:10.1056/nejm199406303302603
202. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. DOI:10.7326/0003-4819-150-9-200905050-00006
203. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766-72. DOI:10.1373/clinchem.2006.077180
204. Chazov EI. Diseases of the cardiovascular system (II). Ed. by academician EI Chazov. Manual of cardiology in four volumes. Vol. 4. Moscow: Praktik, 2014 (in Russian).
205. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):S1-87. DOI:10.1016/j.kint.2020.11.003
206. Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J. 2007;28(7):836-41. DOI:10.1093/eurheartj/ehm027
207. Wokhlu A, Hodge DO, Monahan KH, et al. Long-term outcome of atrial fibrillation ablation: Impact and predictors of very late recurrence. J Cardiovasc Electrophysiol. 2010;21(10):1071-8. DOI:10.1111/j.1540-8167.2010.01786.x
208. Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence among Patients with Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323(3):248-55. DOI:10.1001/jama.2019.21187
209. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380(9838):238-46. DOI:10.1016/S0140-6736(12)60570-4
210. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47(2):219-33. DOI:10.1016/S0008-6363(00)00119-X
211. Olsson LG, Swedberg K, Ducharme A, et al. Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol. 2006;47(10):1997-2004. DOI:10.1016/j.jacc.2006.01.060
212. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology. 1993;43(1):32-6. DOI:10.1212/wnl.43.1_part_1.32
213. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021:1-65. DOI:10.1093/europace/euab065
214. Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of cardiology working group on thrombosis. Eur Heart J. 2017;38(19):1455-62. DOI:10.1093/eurheartj/ehw454
215. Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding: A meta-analysis. Thromb Haemost. 2015;114(4):819-25. DOI:10.1160/TH15-01-0063
216. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(2):554-66. DOI:10.1007/s10620-020-06248-9
217. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. DOI:10.1093/eurheartj/ehy136

И.Е. Чазова1, С.П. Голицын1, Ю.В. Жернакова*1, Е.А. Железнова1, Е.С. Кропачева1, Н.Ю. Миронов1, М.В. Костюкевич1, Л.Ю. Лайович1, М.Д. Уцумуева1, Ю.А. Юричева1, А.Ю. Литвин1,2, Е.М. Елфимова1, А.Н. Рогоза1, Е.П. Панченко1

1 ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия;
2 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*juli001@mail.ru

________________________________________________

Irina E. Chazova1, Sergei P. Golitsyn1, Juliya V. Zhernakova*1, Ekaterina A. Zheleznova1, Ekaterina S. Kropacheva1, Nikolai Iu. Mironov1, Marina V. Kostiukevich1, Lada Iu. Laiovich1, Madina D. Utsumueva1, Iuliia A. Iuricheva1, Alexander Yu. Litvin1,2, Evgeniia M. Elfimova1, Anatolii N. Rogoza1, Elizaveta P. Panchenko1

1 National Medical Research Center of Cardiology, Moscow, Russia;
2 Pirogov Russian National Research Medical University, Moscow, Russia
*juli001@mail.ru